Innovate Biopharmaceuticals Doses First Patient in Phase 3 Clinical Trial CeD LA3001
Innovate Biopharmaceuticals (NASDAQ:INNT) has announced it has dosed the first patient in its Phase 3 clinical trial, CeD LA 3001. As quoted in the press release: This marks the first time any company has dosed a patient in a Phase 3 trial for celiac disease. Larazotide acetate, or INN-202, is Innovate’s leading drug candidate for …
Innovate Biopharmaceuticals (NASDAQ:INNT) has announced it has dosed the first patient in its Phase 3 clinical trial, CeD LA 3001.
As quoted in the press release:
This marks the first time any company has dosed a patient in a Phase 3 trial for celiac disease.
Larazotide acetate, or INN-202, is Innovate’s leading drug candidate for the treatment of celiac disease. The drug is a tight junction regulator designed to help restore “leaky” or open junctions to a normal state. Celiac disease affects approximately 1% of the U.S. population, more than 3 million Americans, and is a high unmet need with no FDA approved treatments.
This Phase 3 study is a national, multicenter, double-blind, placebo-controlled, randomized, parallel-group trial that is expected to enroll approximately 600 patients. The study’s primary objective is to evaluate larazotide acetate as an adjunct therapy for patients with celiac disease who still experience symptoms despite being on a gluten-free diet. Larazotide is an oral therapy taken prior to meals, up to 3 times per day. Larazotide is not systemically absorbed and has a well-established safety profile.
Patrick Griffin, M.D., F.A.C.P., Innovate’s Chief Medical Officer said, “We are thrilled to announce the first patient dosed in our Phase 3 trial. We believe larazotide will have a meaningful impact on celiac patients and provide a therapy where none is approved. Progressing this trial is another step towards bringing a potentially groundbreaking therapy for celiac patients globally.”
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1836.17 | +5.17 | |
Silver | 21.41 | +0.27 | |
Copper | 3.78 | +0.04 | |
Palladium | 1956.43 | +79.44 | |
Platinum | 919.00 | +8.01 | |
Oil | 107.61 | -0.01 | |
Heating Oil | 4.24 | 0.00 | |
Natural Gas | 6.14 | -0.08 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.